Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Innovator

Tema Heart & Health ETF (HRTS)

Ticker HRTS · Since 2023-11-21 · · Holdings as of May 31, 2026

Expense ratio
0.75%$75/yr per $10k
1-yr return
+23.6%as of Dec 2025
Net assets
$51.9Mall share classes
Holdings
45

Bottom line

Is HRTS a good fund? The bottom line

HRTS is a managed health care sector ETF from Innovator.

Its expense ratio is 0.75% — about $75 a year on every $10,000 invested, cheaper than 66% of health care sector funds we track.

It returned +23.6% over one year (as of Dec 31, 2025, per its prospectus).

With $51.9 million in net assets and 45 holdings, its largest position is Eli Lilly & Co (11.5%) and the top 10 make up 49.1% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 57% top-holdings overlap).

Updated Nov 19, 2026

What HRTS invests in

Tema Heart & Health ETF ( formerly, Tema GLP-1, Obesity & Cardiometabolic ETF ) (the Fund) seeks to provide long-term growth of capital.

Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions (CDC). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms…

From the fund's prospectus (filed Jun 29, 2026).

HRTS performance

Fund calendar-year total returns, 2024–2025 2024: +3.6%; 2025: +23.6% +3.6% 2024 +23.6% 2025
Fund gain (+)
Average annual total returns
1 yr5 yr10 yr
HRTS+23.6%——
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full HRTS performance history →

What HRTS costs

On a $10,000 investment, HRTS's 0.75% expense ratio costs about $75 a year. The prospectus estimates $1,168 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full HRTS fee table →

HRTS top 10 holdings

#Holding% of fund
1Eli Lilly & Co LLY11.52%
2UnitedHealth Group Inc UNH5.24%
3Novo Nordisk A/S NOVOB5.24%
4Roche Holding AG RHHBY4.50%
5Merck & Co Inc MRK4.27%
6AstraZeneca PLC AZN4.00%
7Thermo Fisher Scientific Inc TMO3.97%
8Johnson & Johnson JNJ3.59%
9Gilead Sciences Inc GILD3.43%
10Novartis AG NOVN3.38%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 49.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to HRTS

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%57% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%59% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%57% Compare
iSharesIXJ iShares Global Healthcare ETF0.38%64% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%56% Compare
SchwabSWHFX Schwab Health Care Fund0.8%57% Compare

More funds like HRTS →

HRTS FAQ

What is the expense ratio of HRTS?
HRTS's expense ratio is 0.75%, which works out to about $75 a year for every $10,000 invested. The prospectus estimates total costs of $1,168 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HRTS a good investment?
It depends on your goals, but the data points to: a typical fund for its category. This is general information, not personalized advice.
What does HRTS hold?
HRTS's largest holdings are Eli Lilly & Co (11.5%), UnitedHealth Group Inc (5.2%), Novo Nordisk A/S (5.2%), Roche Holding AG (4.5%), Merck & Co Inc (4.3%). It holds 45 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is a cheaper alternative to HRTS?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 57% with HRTS and charges 0.08%.
Who manages HRTS?
HRTS is offered by Innovator through Tema ETF Trust.